U.S. C-Reactive Protein Testing Market Size, Share, Trends, & Industry Analysis Report By Assay Type (Immuno-turbidimetric Assay, ELISA, Clinical, Non-clinical, Chemiluminescence Immunoassay, and Others), By Detection Range, By Disease Area, By End Use– M

The u.s. c-reactive protein testing market size is expected to reach USD 1,253.69 million by 2034, according to a new study by Polaris Market Research. The report “U.S. C-Reactive Protein Testing Market Share, Size, Trends, Industry Analysis Report: By Assay Type (Immuno-turbidimetric Assay, ELISA, Clinical, Non-clinical, Chemiluminescence Immunoassay, and Others), By Detection Range, By Disease Area, By End Use; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

C-reactive protein (CRP) testing measures levels of CRP, a liver-produced protein that rises during inflammation. It helps clinicians assess infection severity, autoimmune flare-ups, or tissue injury. High-sensitivity CRP (hs-CRP) also predicts cardiovascular risk. Doctors use it alongside symptoms and other tests for diagnosis and treatment tracking. CRP testing is fast, widely available, and cost-effective, making it a frontline inflammatory marker in global clinical practice, though interpretation requires context to avoid misdiagnosis.

In the U.S., CRP testing is routinely ordered by physicians across specialties, especially in cardiology, rheumatology, and primary care. Medicare and private insurers often cover it for diagnosing infections, monitoring chronic inflammatory diseases, or assessing cardiovascular risk via hs-CRP. Labs use standardized assays, ensuring consistent national results. Public health initiatives promote hs-CRP for heart disease screening in intermediate-risk patients. However, U.S. guidelines caution against overuse, emphasizing CRP as an adjunct tool.

U.S. C-Reactive Protein Testing Market Report Highlights

In terms of assay type, the immuno-turbidimetric assay segment accounted for a major revenue share in 2024 due to its widespread adoption in clinical laboratories and hospitals.

The chemiluminescence immunoassay segment is expected to grow at a rapid pace during the assessment period owing to its superior sensitivity and specificity, which make it highly effective in detecting low CRP concentrations for early disease diagnosis.

Based on detection range, the hs (high sensitivity) CRP segment is projected to grow at a robust pace in the coming years, owing to its critical role in cardiovascular risk assessment and preventive healthcare.

In terms of disease area, the cardiovascular diseases segment held the largest revenue share in 2024 due to healthcare providers widely adopted CRP testing to evaluate inflammation levels linked to heart conditions.

Based on end use, the hospitals segment dominated the revenue share in 2024 as they serve as the primary centers for diagnosing and managing a wide range of acute and chronic conditions.

A few key market players include Abbott Laboratories; Boditech Med; F. Hoffmann-La Roche Ltd; Getein Biotech; HORIBA Ltd; Merck KGaA; Quest Diagnostics Incorporated; Randox Laboratories; Siemens Healthineers; and Thermo Fisher Scientific, Inc.

Polaris Market Research has segmented the market report on the basis of assay type, detection range, disease area, end use:

By Assay Type Outlook (Revenue, USD Million, 2020–2034)

Immuno-turbidimetric Assay

ELISA

Clinical

Non-clinical

Chemiluminescence Immunoassay

Others

By Detection Range Outlook (Revenue, USD Million, 2020–2034)

hs (high sensitivity) CRP

Conventional CRP

cCRP

By Disease Area Outlook (Revenue, USD Million, 2020–2034)

Cardiovascular Diseases

Cancer

Rheumatoid Arthritis

Inflammatory Bowel Disease

Endometriosis

Lupus

Others

By End Use Outlook (Revenue, USD Million, 2020–2034)

Clinics

Hospitals

Laboratories

Assisted Living Healthcare Facilities

Home Care Settings

Others Show more